bluebird bio is a biotechnology company focused on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. Co.'s programs in severe genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease; and elivaldogene autotemcel. Co.'s programs in oncology are focused on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor T cell therapies. Idecabtagene vicleucel, or ide-cel, and bb21217 are CAR-T cell product candidates for the treatment of multiple myeloma and partnered under Co.'s collaboration arrangement with Bristol-Myers Squibb. The BLUE stock yearly return is shown above.
The yearly return on the BLUE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BLUE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|